Schernthaner, Guntram; Drexel, Heinz; Moshkovich, Evgeny; Zilaitiene, Birute; Martinka, Emil; Czupryniak, Leszek; Várkonyi, Tamás; Janež, Andrej; Ducena, Kristine; Lalić, Katarina; Tankova, Tsvetalina; Prázný, Martin; Smirčić Duvnjak, Lea; Sukhareva, Olga; Sourij, Harald (2019). SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. BMC Endocrine Disorders, 19(1), p. 64. BioMed Central 10.1186/s12902-019-0387-y
|
Text
SchernthanerG_SGLT2InhibitorsinT2D_BMCEndorineDisorders.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (713kB) | Preview |
BACKGROUND
For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME.
EXPERT OPINION
To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence.
CONCLUSION
CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology |
UniBE Contributor: |
Drexel, Heinz |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1472-6823 |
Publisher: |
BioMed Central |
Language: |
English |
Submitter: |
Isabel Lorenz |
Date Deposited: |
12 Dec 2019 09:28 |
Last Modified: |
05 Dec 2022 15:33 |
Publisher DOI: |
10.1186/s12902-019-0387-y |
PubMed ID: |
31208401 |
Uncontrolled Keywords: |
Canagliflozin Cardiovascular disease Dapagliflozin Empagliflozin SGLT2 inhibitor Type 2 diabetes |
BORIS DOI: |
10.7892/boris.136395 |
URI: |
https://boris.unibe.ch/id/eprint/136395 |
Actions (login required)
 |
Edit item |